NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets open in 4 hrs 2 mins

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
45.03+1.42 (+3.26%)
At close: 4:00 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close43.61
Bid0.00 x
Ask46.40 x 500
Day's Range42.75 - 45.43
52 Week Range31.25 - 57.82
Avg. Volume917,493
Market Cap3.91B
PE Ratio (TTM)-30.99
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Hedge Funds Are Dumping CSRA Inc (CSRA)
    Insider Monkey20 hours ago

    Hedge Funds Are Dumping CSRA Inc (CSRA)

    We at Insider Monkey have gone over 742 13F filings that hedge funds and prominent investors are required to file by the government. The 13F filings show the funds’ and investors’ portfolio positions as of September 30. In this article, we look at what those funds think of CSRA Inc (NYSE:CSRA) based on that data. […]

  • PR Newswireyesterday

    Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology

    SAN DIEGO, Dec. 5, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced today that two abstracts representing additional data from several clinical trials of the investigational drug INGREZZATM (valbenazine) are being presented at the Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, Florida. The posters include an evaluation of the safety and effectiveness of long-term dosing of INGREZZA in the treatment of tardive dyskinesia. "We are pleased to share the positive and compelling long-term treatment data of INGREZZA in tardive dyskinesia patients with the broader scientific community," said Chris O'Brien, M.D. Chief Medical Officer of Neurocrine Biosciences.

  • Market Realist5 days ago

    Uterine Fibroids Segment May Offer Opportunity for NBIX

    According to MarketScan and Truven Health Analytics, approximately 9 million women in the US need therapy for symptoms related to uterine fibroids (or UF).